Previous Close | 6.36 |
Open | 6.25 |
Bid | 6.21 x 1800 |
Ask | 6.60 x 900 |
Day's Range | 6.11 - 6.49 |
52 Week Range | 1.93 - 8.56 |
Volume | 459,693 |
Avg. Volume | 1,850,281 |
Market Cap | 544.247M |
Beta (5Y Monthly) | 1.11 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.05 |
Earnings Date | Nov 05, 2020 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 6.70 |
Pfizer sees coronavirus vaccines as a "durable" business, one executive said recently. But don't expect Pfizer stock to be hung up on Covid-19 in 2021. The company sees plenty of catalysts.
The shares lost about half of their value after the company disclosed disappointing trial results for a gene therapy meant to cure Duchenne muscular dystrophy.
The drop came after Sarepta Therapeutics (NASDAQ: SRPT) reported disappointing clinical results for experimental gene therapy SRP-9001 in treating rare genetic disease Duchenne muscular dystrophy (DMD). Sarepta's problem was that SRP-9001 didn't meet the primary functional endpoint of its clinical study. Just because SRP-9001 failed in a clinical study doesn't necessarily mean that SGT-001 will.